TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
This transcript has been edited for clarity. John Kane, MD: I am Dr John Kane. I am a professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, New ...
Switching to clozapine after a first schizophrenia relapse was associated with a lower risk of second relapse compared with other strategies, a population-based cohort study in Finland found. The risk ...
John M. Kane, MD: When someone first develops a schizophrenia illness, I think one of our biggest challenges is helping that person to prevent the recurrence of a psychotic episode. Someone who ...
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kane: In talking ...
John M. Kane, MD: Jeff, what about the causes and predictors of relapse? Jeffrey A. Lieberman, MD: The predictors of relapse, in part, depend on a lot of the causes, in the sense that the causal ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Hi, everyone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback